Johnson & Johnson (FRA:JNJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 423.35B |
| Revenue (ttm) | 78.81B |
| Net Income (ttm) | 21.48B |
| Shares Out | n/a |
| EPS (ttm) | 8.85 |
| PE Ratio | 19.71 |
| Forward PE | 18.64 |
| Dividend | 4.57 (2.57%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 382 |
| Average Volume | 554 |
| Open | 176.30 |
| Previous Close | 178.24 |
| Day's Range | 176.10 - 178.06 |
| 52-Week Range | 129.00 - 183.20 |
| Beta | n/a |
| RSI | 55.64 |
| Earnings Date | Jan 21, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips
The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite. The index's top payers dish up to 6.8%.
Johnson & Johnson Reports Durable Responses With RYBREVANT In Metastatic Colorectal Cancer
(RTTNews) - Johnson & Johnson (JNJ) announced new longer-term follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating RYBREVANT (amivantamab-vmjw), a bispecific antibody targe...
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were also seen in patients with liver m...
January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its single share price. Analyst projections suggest the top ten Dow Dogs could delive...
Johnson & Johnson (JNJ) Target Price Raised by Bernstein to $208 | JNJ Stock News
Johnson & Johnson (JNJ) Target Price Raised by Bernstein to $208 | JNJ Stock News
Johnson & Johnson announces drug pricing deal with Trump admin
Johnon & Johnson said late Thursday it will lower prices for certain prescription drugs and match the rates in other countries, the latest pharmaceutical company to strike a deal with the Trump admini...
2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio
AbbVie and Johnson & Johnson have resilient, noncyclical businesses. They are also outstanding dividend payers.
Johnson & Johnson (JNJ) Agrees to Price Cuts Amid Tariff Exemption Deal
Johnson & Johnson (JNJ) Agrees to Price Cuts Amid Tariff Exemption Deal
J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.
Cramer's Mad Dash: Johnson & Johnson
CNBC's Jim Cramer delivers his daily Mad Dash.
Cramer’s Mad Dash: Johnson & Johnson
CNBC’s Jim Cramer delivers his daily Mad Dash.
Stocks to watch on Friday: TSM, GM, BABA, JNJ
The Zacks Analyst Blog Highlights Johnson & Johnson, Caterpillar, Qualcomm, Fossil and Jones Soda
Johnson & Johnson is gaining momentum as innovative medicines and a strengthening MedTech business support growth despite key patent headwinds.
Johnson & Johnson Strikes Deal With White House to Lower Drug Prices
Trump administration secures deal with Johnson & Johnson to reduce price of some medicines
Johnson & Johnson Secures Tariff Exemption Deal In Exchange For Drug Price Cuts
Johnson & Johnson (NYSE: JNJ) struck a deal with the Trump administration on Thursday to lower drug prices for U.S. consumers in exchange for exemptions from tariffs. The details of the agreement rem...
Johnson & Johnson In Deal With Trump Administration To Cut Drug Prices, Get Tariff Exemption
(RTTNews) - Drug major Johnson & Johnson has announced an agreement with the Trump Administration to lower drug prices, enabling millions of Americans to access medicines at significantly discounted r...
Johnson & Johnson (JNJ) Agrees to Drug Price Reduction Deal
Johnson & Johnson (JNJ) Agrees to Drug Price Reduction Deal
Johnson & Johnson enters pact with Trump admin for drug discounts
Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices
The agreement provides Johnson & Johnson's pharmaceutical products an exemption from tariffs, the company said.
Johnson & Johnson (JNJ) Expands U.S. Manufacturing with New Facilities
Johnson & Johnson (JNJ) Expands U.S. Manufacturing with New Facilities
Johnson & Johnson strikes deal with U.S. government to lower drug prices
Johnson & Johnson said on Thursday that it has reached an agreement with the U.S. President administration to cut drug prices for Americans.
Johnson & Johnson (JNJ) Collaborates with Administration to Lower Drug Costs
Johnson & Johnson (JNJ) Collaborates with Administration to Lower Drug Costs
Johnson & Johnson reaches deal with US government to lower drug prices
Johnson & Johnson said on Thursday it has reached a agreement with U.S. President Donald Trump's administration to cut drug prices for Americans in exchange for exemptions from U.S. tariffs.
Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trum...
Top Analyst Reports for Johnson & Johnson, Caterpillar and Qualcomm
JNJ is leaning on Innovative Medicine growth and MedTech momentum to offset the Stelara patent cliff as it heads into 2026.